

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LUYE PHARMA GROUP LTD.**

**绿叶制药集团有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 02186)**

### **VOLUNTARY ANNOUNCEMENT**

#### **LUYE PHARMA GRANTED EXCLUSIVE RIGHTS TO COMMERCIALIZE NEW DRUG RIVASTIGMINE MD IN SWITZERLAND TO ZAMBON**

The board of directors (the “**Board**”) of Luye Pharma Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Luye Pharma Switzerland AG (“**Luye Switzerland**”), a wholly owned subsidiary of the Company, and Zambon Switzerland (“**Zambon**”) have entered into an agreement under which Zambon was granted the exclusive rights to commercialize the new drug, Rivastigmine Multi-Day Transdermal Patch (“**Rivastigmine MD**” or “**LY30410**”), in Switzerland.

Alzheimer’s disease remains a major global health issue, and the number of patients is constantly growing. According to the “World Alzheimer Report 2019”, it is estimated that there are over 50 million people living with dementia globally, a figure which is set to more than triple, to 152 million by 2050. Over 50% of Alzheimer’s patients’ caregivers indicated that their personal health had suffered as a result of caring responsibilities, with the annual cost of dementia treatment globally estimated at around US\$1 trillion.

Progression of new drug development in the field of Alzheimer’s disease is relatively slow, and at present there are only a very limited number of therapeutic options available to patients. Rivastigmine is a first-line drug in the treatment of dementia associated with Alzheimer’s disease and is currently marketed worldwide.

Rivastigmine MD was developed by the Group and has received marketing authorization for several European countries. Sales in European markets are covered by the Group’s local affiliates and partners. The Group will apply for the Marketing Authorization for this product in Switzerland.

With global trends in population aging, the Board believes that Rivastigmine MD has promising market prospects and will enrich the Group's future product portfolio. The Board also believes that Zambon, as a well-known pharmaceutical company with extensive central nervous system (CNS) experience and a strong business operation system, will increase the accessibility of the product to patients in the country to address their unmet demands.

## **ABOUT RIVASTIGMINE MD**

Rivastigmine MD is a twice-weekly innovative patch formulation for the treatment of mild to moderate dementia associated with Alzheimer's disease. It was developed by the Group on its proprietary transdermal patch platform and is one of the Group's core products in the CNS therapeutic field.

Rivastigmine is in a class of medicines called cholinesterase inhibitors. These medicines can improve cognitive functions such as memory and thinking by increasing the amount of certain natural substance in the brain and amplifying the communication channels between nerve cells, which are less active in individuals with mild to moderate Alzheimer's disease. The drug is currently available in the form of tablets and patches.

In addition to Europe, Rivastigmine MD will also be registered in other major global markets, including China, Japan and other countries or regions. In September 2020, the product was approved by the Centre for Drug Evaluation of the National Medical Products Administration of the People's Republic of China to initiate clinical trials in the country. In February 2021, the Group granted the exclusive development and commercialization rights of Rivastigmine MD in Japan to Towa Pharmaceutical Co., Ltd..

## **ABOUT ZAMBON**

Zambon is a multinational pharmaceutical company committed to innovating cure and care to improve patients' lives. With ambitious plans for growth, its goal is to improve people's health through the development of innovative and quality medicines.

Zambon products are commercialized in 87 countries. The company has 23 subsidiaries in three different continents — Europe, America and Asia — and owns manufacturing facilities in Italy, Switzerland, China and Brazil.

Zambon has now taken a new role in the industry. In addition to pain and diseases of the respiratory system and urological system, Zambon is establishing a global pipeline and introducing important treatments for serious diseases such as Parkinson's Disease, Cystic Fibrosis, Bronchiolitis Obliterans Syndrome and Non-cystic Fibrosis Bronchiectasis.

Zambon was established in 1906 in Italy and today counts around 2,400 employees all over the world.

By Order of the Board  
**LUYE PHARMA GROUP LTD.**  
**Liu Dian Bo**  
*Chairman*

Hong Kong, 10 November 2021

*As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. Sun Xin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.*